{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:55:19Z","timestamp":1792839319460,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s12664-018-0876-3","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T03:53:01Z","timestamp":1535946781000},"page":"424-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study"],"prefix":"10.1007","volume":"37","author":[{"given":"Riyaz U.","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal Ahmad","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sozia Mohammad","family":"Sofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq Saif","family":"Andrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Showkat Ali","family":"Zargar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cgh.2007.04.027","volume":"5","author":"GC Nguyen","year":"2007","unstructured":"Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol. 2007;5:1092\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","volume":"133","author":"J Fernandez","year":"2007","unstructured":"Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818\u201324.","journal-title":"Gastroenterology"},{"key":"876_CR3","first-page":"788","volume":"17","author":"A Maroto","year":"1993","unstructured":"Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 1993;17:788\u201393.","journal-title":"Hepatology"},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/0016-5085(89)91704-6","volume":"97","author":"J Fernandez-Seara","year":"1989","unstructured":"Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304\u201312.","journal-title":"Gastroenterology"},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0002-9343(70)80074-2","volume":"49","author":"ET Schroeder","year":"1970","unstructured":"Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma renin level in hepatic cirrhosis: relation to functional renal failure. Am J Med. 1970;49:186\u201391.","journal-title":"Am J Med"},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2007-1007296","volume":"14","author":"JH Henriksen","year":"1994","unstructured":"Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis. 1994;14:35\u201343.","journal-title":"Semin Liver Dis"},{"key":"876_CR7","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","volume":"48","author":"G Garcia-Tsao","year":"2008","unstructured":"Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48:2064\u201377.","journal-title":"Hepatology"},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"P Gines","year":"2010","unstructured":"Gines P, Angeli P, Lenz K, et al. EASL clinical practice guidelines on the management of ascites- spontaneous bacterial peritonitis- and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397\u2013417.","journal-title":"J Hepatol"},{"key":"876_CR9","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690\u20137.","journal-title":"Hepatology"},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/jhep.2002.34343","volume":"36","author":"C Duvoux","year":"2002","unstructured":"Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002;36:374\u201380.","journal-title":"Hepatology"},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","volume":"14","author":"C Halimi","year":"2002","unstructured":"Halimi C, Bonnard P, Bernard B, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002;14:153\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective-nonrandomized study. Hepatology. 2002;36:941\u20138.","journal-title":"Hepatology"},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","volume":"134","author":"M Martin-Llahi","year":"2008","unstructured":"Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352\u20139.","journal-title":"Gastroenterology"},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","volume":"53","author":"S Neri","year":"2008","unstructured":"Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830\u20135.","journal-title":"Dig Dis Sci"},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized-prospective-double-blind- placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360\u20138.","journal-title":"Gastroenterology"},{"key":"876_CR16","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","volume":"17","author":"I Colle","year":"2002","unstructured":"Colle I, Durand F, Pessione F, et al. Clinical course- predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"876_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","volume":"18","author":"P Solanki","year":"2003","unstructured":"Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective-randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"876_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong F, Pantea L, Sniderman K. Midodrine-octreotide-albumin- and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55\u201364.","journal-title":"Hepatology"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.23286","volume":"51","author":"LL Gluud","year":"2010","unstructured":"Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576\u201384.","journal-title":"Hepatology"},{"key":"876_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","volume":"47","author":"C Alessandria","year":"2007","unstructured":"Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective- randomized- unblended- pilot study. J Hepatol. 2007;47:499\u2013505.","journal-title":"J Hepatol"},{"key":"876_CR21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","volume":"103","author":"P Sharma","year":"2008","unstructured":"Sharma P, Kumar A, Shrama BC, Sarin SK. An open label- pilot- randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103:1689\u201397.","journal-title":"Am J Gastroenterol"},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","volume":"56","author":"V Singh","year":"2012","unstructured":"Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56:1293\u20138.","journal-title":"J Hepatol"},{"key":"876_CR23","first-page":"1310","volume":"56","author":"F Salerno","year":"2007","unstructured":"Salerno F, Gerbes A, Gines P, et al. Diagnosis-prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310\u20138.","journal-title":"Gut"},{"key":"876_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","volume":"62","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968\u201374.","journal-title":"J Hepatol"},{"key":"876_CR25","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","volume":"362","author":"P Gines","year":"2003","unstructured":"Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003;362:1819\u201327.","journal-title":"Lancet"},{"key":"876_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","volume":"55","author":"DT Boyer","year":"2011","unstructured":"Boyer DT, Sanyal JA, Garcia-Taso G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315\u201321.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"876_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0973-6883(11)60051-0","volume":"1","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Madan K, Prakash S, Sreenivas V, Khanal SP, Acharya SK. A randomized controlled trial of terlipressin and albumin versus albumin-low dose dopamine and frusemide in hepatorenal syndrome. J Clin Exp Hepatol. 2011;1 Suppl 1:23\u20134.","journal-title":"J Clin Exp Hepatol"},{"key":"876_CR28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","volume":"5","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Shalimar, Vishnubhatla S, et al. Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine- furosemide-and albumin in hepatorenal syndrome. J Clin Exp Hepatol. 2015;5:276\u201385.","journal-title":"J Clin Exp Hepatol"},{"key":"876_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","volume":"40","author":"T Restuccia","year":"2004","unstructured":"Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40:140\u20136.","journal-title":"J Hepatol"},{"key":"876_CR30","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1097\/TP.0b013e3181a4430b","volume":"87","author":"X Xu","year":"2009","unstructured":"Xu X, Ling Q, Zhang M, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation. 2009;87:1514\u20139.","journal-title":"Transplantation"},{"key":"876_CR31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/lt.22395","volume":"17","author":"TD Boyer","year":"2011","unstructured":"Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for type 1 hepatorenal syndrome type 1. Liver Transpl. 2011;17:1328\u201332.","journal-title":"Liver Transpl"},{"key":"876_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10620-011-1861-1","volume":"57","author":"M Olivera-Martinez","year":"2012","unstructured":"Olivera-Martinez M, Sayles H, Vivekanandan R, et al. Hepatorenal syndrome: are we missing some prognostic factors. Dig Dis Sci. 2012;57:210\u20134.","journal-title":"Dig Dis Sci"},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/liv.12179","volume":"33","author":"S Ghosh","year":"2013","unstructured":"Ghosh S, Choudhary NS, Sharma AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33:1187\u201393.","journal-title":"Liver Int"},{"key":"876_CR34","doi-asserted-by":"publisher","first-page":"e107466","DOI":"10.1371\/journal.pone.0107466","volume":"9","author":"AP Nassar Junior","year":"2014","unstructured":"Nassar Junior AP, Farias AQ, Albuquerque LA, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systemic review and meta-analysis. PLoS One. 2014;9:e107466.","journal-title":"PLoS One"},{"key":"876_CR35","first-page":"30","volume":"64","author":"O Goyal","year":"2016","unstructured":"Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1:a prospective-randomized trial. J Assoc Physicians India. 2016;64:30\u20135.","journal-title":"J Assoc Physicians India"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12664-018-0876-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-018-0876-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-018-0876-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T23:21:33Z","timestamp":1567466493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12664-018-0876-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1007\/s12664-018-0876-3","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RUS, HAD, SMA, MSA, GJ, and SAZ declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was taken from all the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that the study was performed in a manner to conform with the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors are solely responsible for the findings and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members or the printer\/publishers are responsible for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}